Results of the Votes of the Combined Shareholders’ General Meeting of November 27, 2025

Core Points - Inventiva, a clinical-stage biopharmaceutical company, focuses on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) and announced the results of its Combined Shareholders' Meeting held on November 27, 2025 [1][10]. Voting Results - All resolutions submitted to the shareholders were adopted, except for resolution 5, which was negatively recommended by the Board of Directors. This resolution aimed to empower the Board to decide on share capital increases for a company savings plan [3][4]. - The Combined Shareholders' Meeting had a total of 441 shareholders represented, with a total of 119,608,674 votes cast, achieving a quorum of 56.432% [5]. - In the ordinary resolutions, the votes for resolutions ranged from 89.7% to 99.9% in favor, with the highest support for resolution 6 [6][7]. - In the extraordinary resolutions, resolution 4 was adopted with 89.9% in favor, while resolution 5 was rejected with only 41.6% support [8][9]. Company Overview - Inventiva is publicly listed on Euronext Paris and Nasdaq, focusing on the research and development of oral small molecule therapies for MASH and other diseases with significant unmet medical needs. The company is currently evaluating lanifibranor in a pivotal Phase 3 clinical trial [10][11].